Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
Abstract Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP) previously under development as a lipid‐modifying agent that reduces LDL‐cholesterol and increases HDL‐cholesterol in hypercholesterolemic patients. Anacetrapib demonstrates a long terminal half‐life and accumulates in...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wiley
2019-12-01
|
| Cyfres: | Pharmacology Research & Perspectives |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1002/prp2.543 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
